drugset / Trial / NCT00055822

Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer

NCT00055822

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Oblimersen may increase the effectiveness of chemotherapy by making tumor cells more sensitive to the drugs. PURPOSE: Phase I/II trial to study the effectiveness of combining oxaliplatin, fluorouracil, and leucovorin with oblimersen in treating patients who have unresectable, metastatic, or recurrent colorectal cancer.

Timeline

Start
2002-10
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule Intravenous
Subject oblimersen sodium Antisense oligonucleotide Intravenous
Background Leucovorin Small molecule Intravenous
Background fluorouracil Small molecule Intravenous

Indications